Affidea Acquires ZIO AG and Strengthens Outpatient Cancer Care in Switzerland

Greater Collaboration Among Medical Specialties

Affidea is continuously expanding its network of specialized outpatient healthcare services in Switzerland. With ZIO AG, Affidea is expanding its medical expertise in oncology and hematology and creating additional opportunities for interdisciplinary collaboration within its network, which includes diagnostic imaging, pathology, laboratory medicine, genetics, breast medicine, urology, gynecology, and gastroenterology.

In this way, Affidea strengthens interdisciplinary collaboration—from early detection and diagnosis, through specialized medical care and treatment, to follow-up care. Collaboration with referring physicians, hospitals, and other healthcare partners remains a central component of the care model.

Dr. Charles Niehaus, Executive Director of the Affidea Group, explains the acquisition:

«Further expanding access to high-quality cancer care is an important part of Affidea's strategy. The ZIO AG brings extensive clinical expertise and a consistently personalized treatment approach, thereby strengthening our outpatient care network in Switzerland. By integrating oncology, diagnostics, and other medical specialties, we are creating even more coordinated care, in which patients are the focus, from diagnosis through From treatment to follow-up care. Our commitment is it, evidence-based treatment pathways and the expertise of a healthcare group operating throughout Europe, combined with personalized care and continuity of care right here in the community to »that are of great importance to patients and their families."

Marc-André Christinat, CEO of Affidea Switzerland, says:

«With ZIO AG, we are expanding our expertise in oncology and hematology and integrating it even more closely with our existing medical specialties. This opens up additional opportunities for interdisciplinary collaboration and enables us to provide even more comprehensive and personalized care to our patients. We are very pleased to welcome the physicians, nurses, and the entire ZIO AG team to Affidea. Their expertise and deep commitment shape the medical care they provide to their patients every day.»

Continuity for Patients and Partners

ZIO AG’s integrative treatment approach, which Affidea also actively promotes with great dedication and effectiveness, will continue following the acquisition. In addition to chemotherapy, immunotherapy, and targeted therapies, the range of services includes, depending on the individual’s situation, complementary medical methods such as neural therapy or mistletoe therapy, as well as psycho-oncology, oncological exercise therapy, and nutritional counseling. This ensures that ZIO AG’s proven care model is preserved while being integrated into Affidea’s broader medical network.

The existing medical teams and the integrative approach remain central to ZIO AG. The relationships that have developed with patients, referring physicians, hospitals, and other partners will also continue.

Nadine Wilhelm, CEO of ZIO AG, emphasizes:

«ZIO AG has grown significantly over the past ten years. In Affidea, we have found a partner that shares our medical values and opens up new opportunities for growth. It is crucial for us to maintain our integrative approach, our close relationship with our patients, and our high standard of medical care.»

Dr. Boris Hübenthal, CMO of ZIO AG, adds:

«Modern cancer care requires close collaboration among various medical specialties. As part of Affidea, we will be able to combine our expertise in oncology and hematology even more effectively with other specialized areas of expertise in the future. We will continue to expand our close collaboration with referring physicians and our other partners.»

According to the latest figures from the Swiss Cancer League, approximately 48,000 new cases of cancer are diagnosed in Switzerland each year.¹ Behind these numbers are patients and their families, who rely on both specialized medical expertise and continuous, personalized care. By expanding its outpatient care network, Affidea aims to integrate these elements even more closely and enable even better-coordinated care—from diagnosis through treatment to follow-up care.

Affidea Switzerland at a Glance with ZIO AG

• 46 centers in Switzerland
• more than 1,000 employees
• 200 doctors
• about 280,000 consultations annually
• diagnostic imaging, laboratory medicine, specialized medicine, and cancer care

About the Center for Integrative Oncology (ZIO AG)
The Center for Integrative Oncology was founded in 2015 and operates six locations that focus on primary outpatient care in the field of oncology and hematology. Today, more than 20 oncologists and hematologists, as well as other physicians in complementary specialties, work at the ZIO, forming a high-quality and well-functioning network across all locations. The ZIO maintains well-established partnerships with public and private hospitals as well as specialized outpatient services in the greater Zurich area. It currently employs a total of just under 100 staff members, and its services play an important and growing role in providing comprehensive primary medical care in the region.

www.zio.ch

About Affidea Switzerland
Affidea Switzerland is a leading provider of outpatient healthcare services with a focus on diagnostic imaging and specialized medicine. In addition to radiology, its services include breast medicine, urology, gastroenterology, and interdisciplinary medical centers. The company prioritizes patient safety and a consistently quality-focused patient experience. Affidea’s imaging facilities have been awarded five stars by the European Society of Radiology as part of the Eurosafe Wall of Stars program. Affidea has been active in Switzerland since 2007 and conducts over 280,000 consultations annually. Today, more than 1,000 professionals work for the company, including 200 physicians, spread across 46 centers and 12 laboratories, three of which are pathology laboratories. Affidea Switzerland is headquartered in Bulle.

www.affidea.ch

About Affidea Group
The Affidea Group is a leading pan-European provider of specialized healthcare services, particularly in the areas of cancer care, outpatient medical centers, and advanced diagnostic imaging. The company was founded in 1991 and today operates more than 450 centers in 14 countries, serving over 15 million patients annually. Due to its achievements in patient safety, Affidea is recognized by the European Society of Radiology (ESR) as the most-awarded provider of diagnostic imaging in Europe. Over 90 percent of its centers are accredited under the ESR’s Eurosafe Wall of Stars program. The majority shareholder is Groupe Bruxelles Lambert (GBL), a leading publicly traded holding company focused on sustainable, long-term value creation and a stable, entrepreneurially oriented shareholder structure.

www.affidea.com

¹Source: Swiss Cancer League, «Cancer in the Switzerland: the »Key Figures,", updated in the November 2025. Annual average for 2018–2022, excluding non-melanoma skin cancer.